Atlas Trials

An 8-Week Refractory Chronic Cough Study (MK-7264-021)

Clinical trial NCT02612623 · COMPLETED

Trial details

NCT number
NCT02612623
Sponsor
Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Refractory Chronic Cough
Start date
2015-12-17
Primary completion
2016-05-04
Enrollment
24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.